ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

New research from the University of Virginia School of Medicine is revealing why traumatic brain injury increases the chance ...

Research published in the Journal of Alzheimer's Disease suggests findings could transform emergency protocols for the 2.5 ...

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...

Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...

Ahmedabad: An antioxidant, epigallocatechin-3-gallate (EGCG), found in green tea, along with other components, was used by ...

A new study identifies molecular factors that promote small vessel disease—and an active drug that can restore impaired ...

Fosun Pharma is spending 1.4 billion Chinese yuan ($200 million) to take on a 53% stake in Green Valley Pharmaceuticals and ...

The Alzheimer’s, Dementia and Parkinson’s (ADP) research team at Nottingham Trent University is working to combat the ...

A shared molecular signature of Alzheimer’s appears across populations once studied in isolation. Alzheimer's disease (AD) ...

University of Virginia School of Medicine researchers have uncovered how and why traumatic brain injury (TBI) increases the risk for Alzheimer's disease, and their work suggests a potential way to ...